Chevy Chase Trust Holdings LLC Sells 16,152 Shares of Boston Scientific Co. (NYSE:BSX)

Chevy Chase Trust Holdings LLC lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 773,620 shares of the medical equipment provider’s stock after selling 16,152 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Boston Scientific were worth $69,100,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Pictet North America Advisors SA boosted its position in Boston Scientific by 2.4% during the fourth quarter. Pictet North America Advisors SA now owns 78,127 shares of the medical equipment provider’s stock valued at $6,978,000 after acquiring an additional 1,837 shares during the last quarter. Compagnie Lombard Odier SCmA boosted its position in Boston Scientific by 74.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 5,402 shares of the medical equipment provider’s stock valued at $483,000 after acquiring an additional 2,302 shares during the last quarter. Catalyst Financial Partners LLC boosted its position in Boston Scientific by 2.2% during the fourth quarter. Catalyst Financial Partners LLC now owns 7,127 shares of the medical equipment provider’s stock valued at $637,000 after acquiring an additional 154 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Boston Scientific by 8.3% during the fourth quarter. Asset Management One Co. Ltd. now owns 696,124 shares of the medical equipment provider’s stock valued at $63,090,000 after acquiring an additional 53,471 shares during the last quarter. Finally, G&S Capital LLC boosted its position in Boston Scientific by 99.3% during the fourth quarter. G&S Capital LLC now owns 27,242 shares of the medical equipment provider’s stock valued at $2,433,000 after acquiring an additional 13,572 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research analyst reports. Raymond James increased their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Barclays increased their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, TD Cowen increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and an average target price of $107.39.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the completion of the transaction, the director now directly owns 24,398 shares of the company’s stock, valued at approximately $2,573,501.04. This trade represents a 32.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 87,326 shares of company stock valued at $8,673,948 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.4 %

NYSE:BSX opened at $106.16 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market cap of $156.47 billion, a price-to-earnings ratio of 84.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $65.00 and a 52 week high of $107.17. The firm has a 50-day moving average price of $95.80 and a two-hundred day moving average price of $87.85.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, equities analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.